Grossmann M, Hoermann R, Gocze P M, Ott M, Berger P, Mann K
Department of Medicine II, University of Munich, Germany.
Eur J Clin Invest. 1995 Nov;25(11):867-73. doi: 10.1111/j.1365-2362.1995.tb01697.x.
Human chorionic gonadotropin (hCG)-like molecules have been reported to be elevated in a substantial fraction of serum samples from patients with various gynaecologic tumours and have been discussed as possible markers in these malignancies. Employing highly sensitive and specific immunoradiometric assays, we determined total hCG-related immunoreactivity (hCG/hCG beta), as well as free alpha-subunit (alpha-SU), common to all glycoprotein hormones, in serum (n = 106) and malignant effusions (n = 26) of women with gynaecologic malignancies. For comparison, we also measured hCG/hCG beta in nonmalignant ascitic fluids (n = 21). HCG/hCG beta serum levels were elevated (> 5 IU L-1) in 39 of 106 patients (37%) with gynaecologic malignancies, whereas free alpha-SU was above normal range only in seven (6.6%). Frequencies of hCG/hCG beta elevations were similar in women with endometrial, (n = 39), cervical (n = 40) and ovarian (n = 27) cancer, being 30%, 35% and 41%, respectively. In malignant ascites (n = 15) and tumour cyst fluids (n = 11) of patients with ovarian cancer, hCG/hCG beta concentrations were significantly higher than in the corresponding serum samples and benign ascitic samples. Free alpha-SU, on the other hand, was increased in only one of 26 malignant effusions. In conclusion, hCG/hCG beta is frequently elevated in serum of patients with endometrial, cervical and ovarian cancer and may serve as a tumour marker in these malignancies, particularly in patients where other markers are negative. In this respect, analysis of ascitic or tumour cyst fluids may be of higher diagnostic value as serum measurements.
据报道，在患有各种妇科肿瘤的患者的大部分血清样本中，人绒毛膜促性腺激素（hCG）样分子水平升高，并且已被讨论作为这些恶性肿瘤的可能标志物。我们采用高灵敏度和特异性的免疫放射分析方法，测定了患有妇科恶性肿瘤的女性血清（n = 106）和恶性积液（n = 26）中与hCG相关的总免疫反应性（hCG/hCGβ）以及所有糖蛋白激素共有的游离α亚基（α-SU）。为作比较，我们还测定了非恶性腹水（n = 21）中的hCG/hCGβ。106例患有妇科恶性肿瘤的患者中，39例（37%）的hCG/hCGβ血清水平升高（> 5 IU/L），而游离α-SU仅7例（6.6%）高于正常范围。子宫内膜癌（n = 39）、宫颈癌（n = 40）和卵巢癌（n = 27）女性中hCG/hCGβ升高的频率相似，分别为30%、35%和41%。在卵巢癌患者的恶性腹水（n = 15）和肿瘤囊液（n = 11）中，hCG/hCGβ浓度显著高于相应的血清样本和良性腹水样本。另一方面，26例恶性积液中只有1例游离α-SU升高。总之，hCG/hCGβ在子宫内膜癌、宫颈癌和卵巢癌患者血清中经常升高，可作为这些恶性肿瘤的肿瘤标志物，特别是在其他标志物为阴性的患者中。在这方面，腹水或肿瘤囊液分析可能比血清检测具有更高的诊断价值。
